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Purpose
The purpose of this study was to compare ramosetron (RAM), aprepitant (APR), and dex-
amethasone (DEX) [RAD] with palonosetron (PAL), APR, and DEX [PAD] in controlling highly-
emetogenic chemotherapy (HEC)–induced nausea and vomiting.     
Materials and Methods
Patients were randomly assigned (1:1) to receive RAD or PAD:RAM (0.3 mg intravenously)
or PAL (0.25 mg intravenously) D1, combined with APR (125 mg orally, D1 and 80 mg orally,
D2-3) and DEX (12 mg orally or intravenously, D1 and 8 mg orally, D2-4). Patients were
stratified by sex, cisplatin-based chemotherapy, and administration schedule. The primary
endpoint was overall complete response (CR), defined as no emesis and no rescue regimen
during 5 days of HEC. Secondary endpoints were overall complete protection (CP; CR+nau-
sea score < 25 mm) and total control (TC; CR+nausea score < 5 mm). Quality of life was 
assessed by Functional Living Index Emesis (FLIE) questionnaire on D0 and D6.
Results
A total of 279 patients receiving RAD (n=137) or PAD (n=142) were evaluated. Overall CR
rates in RAD and PAD recipients were 81.8% and 79.6% (risk difference [RD], 2.2%; 95%
confidence interval [CI], !7.1 to 11.4), respectively. Overall CP and TC rates for RAD and
PAD were 56.2% and 58.5% (RD, !2.3%; 95% CI, !13.9 to 9.4) and 47.5% vs. 43.7% (RD,
3.8%; 95% CI, !7.9 to 15.5), respectively. FLIE total score " 108 (no impact on daily life)
was comparable between RAD and PAD (73.9% vs. 73.4%, respectively). Adverse events
were similar between the two groups. 
Conclusion
In all aspects of efficacy, safety and quality of life, RAD is non-inferior to PAD for the control
of chemotherapy-induced nausea and vomiting in cancer patients receiving HEC.
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Introduction
Chemotherapy-induced nausea and vomiting (CINV) has
been reported as the fifth most feared symptom in cancer 
patients receiving systemic cytotoxic chemotherapy [1,2].
Overwhelming evidence shows that CINV, when not ade-
quately controlled, degrades the quality of life (QOL) of can-
cer patients. Although CINV is feared by cancer patients
receiving highly-emetogenic chemotherapy (HEC), it can be
controlled [2,3].
Based on phase III study data, the triple-drug combination
of ondansetron (OND), dexamethasone (DEX), and aprepi-
tant (APR) was regarded as the standard antiemetic regimen
for cancer patients receiving HEC [4]. Palonosetron (PAL)
has a longer half-life and stronger 5HT3 receptor binding
affinity than other 5HT3 receptor antagonists (5HT3RAs), 
including OND, granisetron (GRA), and dolasetron (DOL)
[5]. Moreover, PAL alone or in combination with DEX exhib-
ited better antiemetic activity than GRA or DOL combined
with DEX for the control of acute and delayed CINV in pati-
ents receiving moderately-emetogenic chemotherapy (MEC)
[6,7]. National comprehensive cancer network guidelines
currently recommend the combination of PAL, APR, and
DEX (PAD) as a standard regimen for controlling HEC-
induced CINV in cancer patients [8]. However, there are no
direct head-to-head comparisons of PAD vs. other 5HT3RAs.
Ramosetron (RAM), a 5HT3RA with a prolonged half-life
and increased receptor binding affinity compared to OND or
GRA [9], has been used widely for CINV prevention in Asia.
The antiemetic activity of RAM was shown to be similar to
that of PAL for controlling MEC-induced CINV [10].
The purpose of this phase IV study was to show the non-
inferiority of the combination of RAM, APR, and DEX (RAD)
compared to PAD in controlling HEC-induced CINV.
Materials and Methods
1. Study design
This prospective, multicenter, single-blind, randomized
phase IV clinical trial was conducted in 10 institutions. Pati-
ents were randomly assigned to RAD or PAD (1:1 ratio). The
study was conducted under single-blind conditions, with
participants not being aware of their assignment group.
Inclusion criteria included age 19-75 years, pathologically-
confirmed malignant disease, and Eastern Cooperative 
Oncology Group performance status 0-2. Patients were sche-
duled to receive HEC on the first day of treatment. Patients
were required to have adequate bone marrow, hepatic, and
renal function. Major exclusion criteria included medica-
tions, medical illness, or medical conditions and procedures
that could affect nausea or vomiting (a complete list of eligi-
bility criteria is provided in the S1 Table).
2. Study treatment
APR (125 mg orally, 1 hour prior to chemotherapy, D1; 80
mg orally, D2-3) and DEX (12 mg, orally or intravenously, 30
minutes prior to chemotherapy, D1; 8 mg, orally, D2-4) were
administered in both arms. The RAM and PAL arms received
RAM (0.3 mg, D1) or PAL (0.25 mg, D1) intravenously 30
minutes before chemotherapy. Rescue antiemetics for severe
nausea/vomiting were administered at the request of the 
patient or upon recommendation by the attending physicians
at any time during the study period.
3. Study endpoints
The primary endpoint was overall complete response (CR),
defined as no vomiting, including retching, and no require-
ment for rescue antiemetics within 5 days of HEC. Secondary
endpoints were CR, complete protection (CP; CR+nausea
score < 25 mm; 0-100 mm), and total control (TC; CR+nausea
score < 5 mm; 0-100 mm) in the acute (0-24 hours), delayed
(D2-5), and overall (D0-5) periods; severity of nausea (deter-
mined using a 0-100 mm visual analog scale); time to first 
occurrence of vomiting; QOL assessed by the validated 
patient self-assessment Functional Living Index Emesis
(FLIE) questionnaire [11]; safety. During the overall period,
patients recorded daily episodes of vomiting or retching, the
degree of nausea, and the use of rescue medication in a diary
and using the Rhodes Index of Nausea and Vomiting Form-
2 (INV-2) [12]. Safety was evaluated based on clinical and
laboratory adverse events (AEs) between the start day and
the day before the next chemotherapy, assessed according to 
National Cancer Institute–Common Terminology Criteria for
Adverse Events (NCI-CTCAE) ver. 4.03 [13].
4. FLIE measurement and scoring
FLIE includes 18 questions divided into two domains: nau-
sea (questions 1-9) and vomiting (questions 10-18) [11]. The
questionnaire was completed on D0 (reflecting daily-life 
activities before chemotherapy) and D6 (to provide informa-
tion on the overall effect of CINV on daily-life activities dur-
ing D1-5). The average score for each domain was summed
and transformed using a pre-specified scoring procedure,
which allowed for a minimum domain score of 6 and a max-
imum of 63. The chi-square test was used to compare the pro-
portion of patients treated with RAM vs. PAL, with ‘no
impact on daily life’ (NIDL) (i.e., individual question scores
> 6 on the 7-point FLIE scale, domain score ! 54, overall FLIE
score ! 108) assessed for the FLIE domains of nausea, vomit-
ing, and combined (i.e., total score).
5. Statistical analysis
The hypothesis was that the CR rate in the RAD arm dur-
ing the overall period would not be inferior to the CR rate in
the PAD arm. A sample size of 135 in each arm allowed an
80% power and one-sided ! level of 0.025 to detect a CR non-
inferiority difference of "15% between the RAD and PAD
groups, assuming the actual CR in each group to be 77% and
77%, respectively. With an expected dropout rate of 15%,
sample size was increased to 146 patients per arm.
Stratified block randomization was conducted with a 1:1
ratio between groups, randomly mixing block sizes of 2 and
4, considering (1) chemotherapeutic regimen (cisplatin vs.
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non-cisplatin), (2) treatment schedule (single-day vs. multi-
ple-day), and (3) sex (male vs. female), as stratification fac-
tors. Patients were assigned according to a pre-defined ran-
domization sequence created by an independent investigator
with no clinical involvement in the trial.
Effectiveness was calculated in the modified intention-to-
treat population, defined as all patients randomly assigned
to a treatment group having received at least one study treat-
ment dose after randomization. Data were analyzed using
SAS ver. 9.4 (SAS Institute Inc., Cary, NC). The two groups
were compared using the chi-square test, Fisher exact test,
and Wilcoxon rank-sum test, as appropriate.
6. Ethical statement
The study protocol was approved by the institutional 
review boards at the Seoul Saint Mary’s Hospital (KC15MI-
MV0785), Kangdong Sacred Heart Hospital (KANGDONG-
2015-05-005), Kangbuk Samsung Hospital (KBSMC 2015-03-
010), Keimyung University Dongsan Hospital (DSMC 2015-
06-060), St. Vincent's Hospital (VC16MIMV0059), Severance
Hospital, Yonsei Cancer Center (4-2015-0414), Pusan Natio-
nal University Hospital (H-1506-003-044), Ajou University
Hospital (AJIRB-MED-CT4-15-083), Chungnam National
University Hospital (CNUH 2015-02-025), Samsung Medical
Center (SMC-2015-01-096) and registered with ClinicalTri-




Between August 2015 and September 2017, a total of 309
patients were screened and 292 eligible patients were ran-
domly assigned (1:1) to receive RAD or PAD (Fig. 1). Patient
characteristics, disease demographics, chemotherapeutic reg-
imens, and administration schedules were well balanced 
between both arms (Table 1).
2. Efficacy
The overall CR rates of RAD and PAD were 81.8% and
79.6% (risk difference [RD], 2.2%; 95% confidence interval
[CI], !7.1 to 11.4). RAD was non-inferior to PAD, as evi-
denced by CR rates in the acute, delayed, and overall periods
(RD, 2.0%, 4.4%, and 2.2%, respectively) (Table 2, Fig. 2A).
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Ramosetron, aprepitant, and
dexamethasone (RAD) (n=146)
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Fig. 1. Complete response rate (A), complete protection rate (B), and total control rate (C) in intention-to-treat population
(n=279) on a daily basis. (A) The risk difference between the two arms was 2.2% (95% confidence interval [CI], –7.1% to
11.4%). (B) The risk difference between the two arms was –2.3% (95% CI, –13.9% to 9.4%). (C) The risk difference between
the two arms was 3.8% (95% CI, –7.9% to 15.5%) using the generalized estimating equation model. HEC, highly-emetogenic
chemotherapy; mITT, modified intention to treatment.
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CP rates in RAD recipients were numerically lower than
in PAD recipients, with efficacy differences in the acute, 
delayed and overall periods of !1.5%, !2.8%, and !2.3%, 
respectively (Table 2), but the non-inferiority of RAD vs.
PAD remained unchanged (Fig. 2B).
TC rates in RAD during all study time periods were 
numerically higher than those in PAD, as evidenced by TC
rates in the acute, delayed, and overall periods (68.6% vs.
64.1% [RD 4.5%], 48.9% vs. 46.5% [RD 2.4%], and 47.5% vs.
43.7% [RD 3.8%], respectively) (Table 2, Fig. 2C).
3. Quality of life                                                       
The total FLIE score with RAD (115.5±17.6) was compara-
ble to that with PAD (114.8±16.7, p=0.745). The proportion
of patients with FLIE score " 108 (NIDL) in RAD (75.0%) was
comparable to that in PAD (73.9%) (RD, 1.09; 95% CI, !9.32
to 11.49; p=0.838). The proportion of patients with FLIE score
" 54 in each of the nausea and vomiting domains in RAD was
numerically higher than in PAD (72.2% vs. 65.9% and 91.2%
vs. 91.3%, respectively), but not statistically significant
Cancer Res Treat. 2020;52(3):907-916
Table 1.  Demographics
Values are presented as number (%) or mean±standard deviation. RAD, ramosetron, aprepitant, and dexamethasone; PAD,
palonosetron, aprepitant, and dexamethasone; GU, genitourinary; GY, gynecology; Gastrointestinal, esophagus, stomach,
colorectum; Others, lymphoma, skin; NA, not available; ECOG, Eastern Cooperative Oncology Group. a)Fisher exact test,
b)Individual chemotherapy regimens are detailed in S2 Table.
RAD (n=137) PAD (n=142) p-value
Sex
Male 86 (62.8) 87 (61.3) 0.796
Female 51 (37.2) 55 (38.7)
Age (yr) 59.4±12.0 60.3±11.8 0.521
Motion sickness
Yes 32 (23.4) 27 (19.0) 0.374
No 105 (76.6) 115 (81.0)
Alcohol drinking
Yes 50 (36.5) 52 (36.6) 0.983
No 87 (63.5) 90 (63.4)
Tumor location
Lung and thymus 59 (43.1) 61 (42.9) 0.074
Breast 32 (23.4) 31 (21.8)
Head and neck 14 (10.2) 25 (17.6)
GU and GY 13 (9.5) 6 (4.2)
Gastrointestinal 9 (6.6) 3 (2.1)
Other 10 (7.3) 16 (11.3)
Stage
I 17 (12.4) 13 (9.2) 0.929
II 28 (20.4) 32 (22.5)
III 36 (26.3) 37 (26.1)
IV 54 (39.4) 58 (40.8)
NA 2 (1.5) 2 (1.4)
ECOG performance status
0 51 (37.2) 51 (35.9) 0.466a)
1 81 (59.1) 89 (62.7)
2 5 (3.6) 2 (1.4)
Cisplatin-based chemotherapyb)
Yes 98 (71.5) 103 (72.5) 0.894
No 39 (28.5) 39 (27.5)
Administration schedule
Single day 84 (61.3) 87 (61.3) > 0.99
Multiple day 53 (38.7) 55 (38.7)
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(p=0.267 and p=0.565, respectively) (Table 3).  
4. Adverse events
A total of 292 patients receiving RAD or PAD were evalu-
ated in the safety cohort. Overall, no new safety signals were
identified. Both RAD and PAD were well tolerated, with 
> 90% of AEs mild or moderate (Table 4). The most common
hematologic and non-hematologic toxicities were neutrope-
nia and anorexia, respectively.
Discussion
PAD is the standard regimen for controlling CINV in can-
cer patients receiving HEC. We conducted a prospective,
multicenter, single-blind, randomized clinical study to prove
the non-inferiority of RAD vs. PAD for the control of HEC-
induced CINV.
The distribution of patients between both treatment groups
was well balanced by patient-related and chemotherapy-
related factors. The primary endpoint of the study was over-
all CR throughout 5 days post-HEC. The CR rate in PAD 
recipients, used as the reference arm, was comparable to
rates in 1,453 patients who were randomized to PAD in
seven randomized controlled trials (RCTs) for HEC-induced
CINV [14-20]; CR rates in the RCTs vs. our study were 86.6%
vs. 93.7%, 73.4% vs. 79.6%, and 69.5% vs. 79.6% in the acute,
delayed, and overall phases, respectively (Table 5). Mean-
while, the overall CR rate (81.8%) with RAD was slightly
higher than in our previous phase III study (77.1%) [21], but
comparable to that with PAD (79.6%). QOL with FLIE was
very similar between RAD and PAD in terms of nausea,
vomiting, and total score. In addition, the proportion of 
patients with FLIE score ! 108 (NIDL) in RAD was compa-
rable to that in PAD. These results strongly support the 
hypothesis that RAD is non-inferior to PAD, as evidenced by
FLIE score as well as CR rates in the acute, delayed, and over-
all phases.
CR, CP, and TC in RAD did not differ from those in PAD.
The number of patients with a FLIE score in the nausea 
domain ! 54 was also higher with RAD than PAD although
it was not statistically significant. Considering that the defi-
nition of CP allows a low level of nausea, unlike TC, the
mechanism of action of RAM may be different from PAL.
Previously, Japanese researchers reported that RAM had
higher affinity for cloned human and rat 5HT3 receptors, as
well as extremely slower dissociation from the human 5HT3
receptor compared with other 5-HT3RAs including alosetron
and cilansetron [22]. Accordingly, there are two possible 
explanations about the conflicting results in our study: (1)
RAM may have stronger binding to 5HT3 receptors present
on enterochromaffin cells; (2) RAM may block the extramem-
brane domain of 5HT3 receptor binding to serotonin more
effectively.
Subgroup analyses by age, sex, chemotherapy regimen,
and tumor type, proved that RAD is non-inferior to PAD. 
Although the subgroup analysis is controversial regarding
statistical significance due to some results exceeding the non-
inferiority margin, RAD and PAD displayed distinct activi-
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Phase
No. (%) Differencea)
RAD (n=137) PAD (n=142) (95% CI)
CR
Acute 131 (95.6) 133 (93.7) 2.0 ("3.3 to 7.2)
Delayed 115 (83.9) 113 (79.6) 4.4 ("4.7 to 13.4)
Overall 112 (81.8) 113 (79.6) 2.2 ("7.1 to 11.4)
CP
Acute 105 (76.6) 111 (78.2) "1.5 ("11.3 to 8.3)
Delayed 82 (59.9) 89 (62.7) "2.8 ("14.3 to 8.6)
Overall 77 (56.2) 83 (58.5) "2.3 ("13.9 to 9.4)
TC
Acute 94 (68.6) 91 (64.1) 4.5 ("6.6 to 15.6)
Delayed 67 (48.9) 66 (46.5) 2.4 ("9.3 to 14.2)
Overall 65 (47.5) 62 (43.7) 3.8 ("7.9 to 15.5) 
RAD, ramosetron, aprepitant, and dexamethasone; PAD, palonosetron, aprepitant, and dexamethasone; 95% CI, 95% confi-
dence interval; CR, complete response; CP, complete protection; TC, total control. a)Difference was calculated as (RAD-PAD).
Table 2. Complete response, complete protection, and total control rates in intention-to-treat population 
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ties regarding different aspects of individual subgroups.
Given the fact that cisplatin-containing HEC was adminis-
tered for all lung cancer patients, RAM seems to be more 
effective for cisplatin-induced nausea and vomiting. Mean-
while, because non- cisplatin chemotherapy was given to all
breast cancer patients, PAL seems to be more effective for
non-cisplatin chemotherapy-induced nausea and vomiting.
FLIE scores in the total, nausea, and vomiting domains
with RAD were quite similar to those with PAD. Patients
with a FLIE total score ! 108 (NIDL) and a FLIE score in the
vomiting domain ! 54 were comparable between both groups,
but the number of patients with a FLIE score in the nausea
domain ! 54 was numerically higher in RAD than PAD.
There is a possibility that the higher TC rate with RAD is 
reflected in a QOL benefit, with a correspondingly greater
proportion of patients with NIDL due to more effective nau-
sea control during the overall period. While this difference
is small, it is encouraging that RAD has some potential to 
improve QOL.
In this study, no new safety signals were identified. More
than 90% of AEs were mild or moderate in intensity. The 
incidence and duration of serious AEs or AEs was low and
similar between both groups.
There are several study limitations. Firstly, because the
study aim was to prove the non-inferiority of RAD vs. PAD,
subgroup analysis was not scheduled. Although subgroup
analysis produced some degree of differences between both
arms, some analysis results did not show statistical signifi-
cance due to the small number of subjects. Secondly, FLIE
questionnaire results were not been collected on day 2, 






























































































Fig. 2. Complete response rate (A), complete protection rate (B), and total control rate (C) in intention-to-treat population
(n=279) on a daily basis. There was no statistical significance by individual date. (A) The risk difference between the two
arms was 2.2% (95% confidence interval [CI], –7.1 to 11.4). (B) The risk difference between the two arms was –2.3% (95%
CI, –13.9 to 9.4). (C) The risk difference between the two arms was 3.8% (95% CI, –7.9 to 15.5) using the generalized estimating
equation model. RAD, ramosetron, aprepitant, and dexamethasone; PAD, palonosetron, aprepitant, and dexamethasone.
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reflecting QOL during the acute period. Delayed emesis neg-
atively influences patient QOL during administration of
HEC and beyond. Both 5HT3RAs demonstrated significant
inhibition against HEC-induced CINV, but did not improve
control of delayed nausea, indicating that unmet needs 
remain for novel antiemetics.
In conclusion, in all aspects of efficacy, safety, and QOL,
our data suggested that RAD was comparable to PAD for
controlling HEC-CINV in cancer patients.
Jin Hyoung Kang, Comparing Ramosetron to Palonosetron in HEC-CINV
Mean±SD or n (%) Differencea) p-value
RAD (n=132) PAD (n=138) (95% CI)
FLIE score
Total 115.5±17.6 114.8±16.7 0.68 (–3.43 to 4.79) 0.745
Nausea domain 54.3±13.9 53.8±13.0 0.48 (–2.74 to 3.70) 0.770
Vomiting domain 61.2±6.5 61.0±6.8 0.27 (–1.33 to 1.87) 0.742
NIDL
Total ! 108 99 (75.0) 102 (73.9) 1.09 (–9.32 to 11.49) 0.838
Nausea domain ! 54 95 (72.0) 91 (65.9) 6.24 (–4.74 to 17.22) 0.267
Vomiting domain ! 54 123 (93.2) 126 (91.3) 1.88 (–4.49 to 8.25) 0.565
FLIE score, the Functional Living Index–Emesis score; NIDL, no impact on daily life; mITT, modified intention to treatment;
SD, standard deviation; RAD, ramosetron, aprepitant, and dexamethasone; PAD, palonosetron, aprepitant, and dexametha-
sone; CI, confidence interval. a)Difference was calculated as (RAD–PAD).
Table 3. FLIE score and proportion of patients reporting NIDL for total, nausea domain, and vomiting domain in the mITT
population 
Table 4.  Safety profile (any adverse events with incidence > 1%)
Values are presented as number (%). Adverse events were graded according to National Cancer Institute–Common Termi-
nology Criteria (CTCAE) ver. 4.03. RAD, ramosetron, aprepitant, and dexamethasone; PAD, palonosetron, aprepitant, and
dexamethasone; AST, aspartate aminotransferase; ALT, alanine aminotransferase.
RAD (n=146) PAD (n=145) p-value
Leukopenia 35 (24.0) 38 (26.1) > 0.05
Neutropenia 41 (28.1) 46 (31.6) > 0.05
Febrile neutropenia 12 (8.3) 9 (6.2) > 0.05
Anemia 30 (20.6) 29 (19.9) > 0.05
Thrombocytopenia 21 (14.4) 17 (11.7) > 0.05
Anorexia 43 (29.5) 47 (32.2) > 0.05
Mucositis 14 (9.6) 19 (13.1) > 0.05
Diarrhea 18 (12.4) 13 (9.0) > 0.05
Abdominal pain 9 (6.2) 7 (4.8) > 0.05
Constipation 24 (16.5) 26 (17.9) > 0.05
Alopecia 27 (18.5) 40 (27.4) > 0.05
Rash 4 (2.8) 4 (2.8) > 0.05
AST elevation 5 (3.5) 5 (3.5) > 0.05
ALT elevation 6 (4.2) 4 (2.8) > 0.05
Hypernatremia 8 (5.5) 11 (7.6) > 0.05
Hyperkalemia 12 (8.3) 13 (9.0) > 0.05
Hypercalcemia 8 (5.5) 8 (5.5) > 0.05
Hypophosphatemia 9 (6.2) 5 (3.5) > 0.05
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